Click below to read the latest news and updates from Arboretum Ventures.
Esperion Therapeutics, Inc. (Nasdaq:ESPR), a clinical-stage biopharmaceutical company focused on developing and commercializing first-in-class, oral, low-density lipoprotein cholesterol (LDL-C) lowering therapies for the treatment of patients with hypercholesterolemia, announced dosing of the first patient in a Phase 2b clinical study of ETC-1002, its lead product candidate, in patients with or without statin intolerance and hypercholesterolemia. The goals of this study, ETC-1002-008, are to compare the LDL-C lowering efficacy of ETC-1002 with ezetimibe and to demonstrate comparable tolerability to ezetimibe, a common therapy for statin intolerance, in the treatment of patients with elevated LDL-C levels.
BAROnova has been selected by Fierce Medical Devices as one of 2013′s Fierce 15 device and diagnostic companies, designating it as one of the most promising companies in the medtech space. BAROnova is a clinical-stage medical-technology company focused on developing non-surgical non-pharmacologic devices to induce weight loss.
NxThera, Inc., a privately held medical device company developing a proprietary water vapor endourology treatment platform, announced that Steven Gange, MD, of Western Urological Clinic and Jean Brown Research in Salt Lake City, Utah, used NxThera’s Rezum® System to enroll and treat the first patients in NxThera’s Rezum II U.S. investigational device exemption (IDE) clinical trial for the treatment of benign prostatic hyperplasia (BPH). The Rezum System is designed to rapidly treat prostate tissue using sterile water vapor, or steam, in an office-based, minimally invasive procedure designed to treat the urethral obstruction caused by BPH.
Tangent Medical, an innovator in IV therapy products and creator of the NovaCath™ Integrated IV Catheter System, won a Gold Stevie® Award in the Best New Product or Service for Health & Pharmaceuticals category and a Silver Stevie® Award for Tech Innovation of the Year (organization with up to 100 employees) at The 11th Annual American Business Awards held in San Francisco on September 16th, 2013.
ArborMetrix, Inc., the leading provider of real-time clinical healthcare analytics, announced that the Michigan Trauma Quality Improvement Program (MTQIP) has chosen its fully integrated, cloud-based registry and analytics platform to drive meaningful analysis and decision support. MTQIP, a Blue Cross Blue Shield of Michigan (BCBSM) Collaborative Quality Initiative (CQI) is using ArborMetrix’s platform to integrate clinical and administrative data collected from participating hospitals to measure outcome variations that will be reported through web-based dashboards. ArborMetrix is also integrating MTQIP’s historic registry data into the new measurement and reporting platform.
ADVANCE Medical, a medical device, equipment and diagnostics distribution company backed by leading United States and Latin American investors, whose mission is to become the commercial partner-of-choice for innovative global medical technology companies looking to commercialize their products into leading physician clinics, hospitals and laboratories in Latin America, announced it has raised $20 million in an equity financing from new investors Aberdare Ventures and Arboretum Ventures, as well as existing investors including Venrock and Jose Bonchristiano.
Esperion Therapeutics, Inc. (NASDAQ: ESPR), a clinical-stage biopharmaceutical company, announced positive top-line results from a Phase 2a study of ETC-1002 when added to statin therapy in patients with elevated levels of low density lipoprotein cholesterol (LDL-C or “bad cholesterol”). The study demonstrated that oral, once-daily ETC-1002 achieved incremental LDL-C lowering of 22 percent at eight weeks, compared with 0 percent in the placebo group, when added to 10mg of atorvastatin (p < 0.0001). ETC-1002 was well tolerated over eight weeks of treatment when added to a statin and no serious adverse events (SAEs) were reported.
Delphinus Medical Technologies, Inc., innovator and developer of the SoftVue™ whole breast ultrasound tomography system, has secured an additional $11 million through a combination of equity and debt financing. Delphinus has filed for clearance with the U.S. Food and Drug Administration and this latest round of funding will further the development of the technology and support commercialization efforts when cleared. Arboretum Ventures and Beringea, LLC co-led this series and are joined by North Coast Technology Investors. The addition of debt venture completed this round.
KFx Medical Corporation announced that it has entered into a license agreement with Smith & Nephew, Inc. relating to its patents used in knotless double row rotator cuff repair. Under the agreement, Smith & Nephew will have the right to promote the use of products and techniques for knotless double row rotator cuff repair as claimed in US Patent number 7,585,311 and related patents and applications for the life of those patents.